This episode currently has no reviews.
Submit ReviewYields dropping to their lowest level in months, as this morning’s inflation report boosted hopes of a rate cut. So is the rate retreat the greenlight for investors to rotate into the laggards? Plus Pfizer’s getting in on the weight loss drug battle. How the pharma giant is moving forward with an obesity pill after encouraging data.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review